Ratings Cerenis Therapeutics CINNOBER BOAT

Equities

0RAG

FR0012616852

Delayed CINNOBER BOAT Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		-.--%	-.--%

Jun. 14	Abionyx: positive response from FDA, share price rises	CF
Jun. 13	ABIONYX Pharma Completes Pre-IND Meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Revenue estimates are regularly revised downwards for the current and coming years.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
CERENIS THERAPEUTICS	-.--%	45.48M	-
VERTEX PHARMACEUTICALS INCORPORATED	+15.85%	122B	B+
REGENERON PHARMACEUTICALS, INC.	+18.91%	113B	B+
ARGENX SE	+5.97%	22.84B	B
BIONTECH SE	-18.63%	20.72B	B+
BEIGENE, LTD.	-13.76%	16.39B	B
GENMAB A/S	-16.61%	16.51B	A-
WUXI APPTEC CO., LTD.	-43.53%	15.83B	A-
NEUROCRINE BIOSCIENCES, INC.	+1.75%	13.49B	C+
SAREPTA THERAPEUTICS, INC.	+28.07%	11.67B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes